Selected article for: "CI cumulative incidence and cumulative incidence"

Author: Patell, Rushad; Bogue, Thomas; Koshy, Anita; Bindal, Poorva; Merrill, Mwanasha; Aird, William C.; Bauer, Kenneth A.; Zwicker, Jeffrey I.
Title: Postdischarge thrombosis and hemorrhage in patients with COVID-19
  • Cord-id: 497nkrk5
  • Document date: 2020_9_10
  • ID: 497nkrk5
    Snippet: Abstract Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state with a high incidence of thrombotic events during hospitalization; however, data examining rates of thrombosis after discharge are limited. We conducted a retrospective observational cohort study of discharged patients with confirmed COVID-19 not receiving anticoagulation. The cohort included 163 patients with median time from discharge to last recorded follow-up of 30 days (interquartile range [IQR], 17-46 day
    Document: Abstract Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state with a high incidence of thrombotic events during hospitalization; however, data examining rates of thrombosis after discharge are limited. We conducted a retrospective observational cohort study of discharged patients with confirmed COVID-19 not receiving anticoagulation. The cohort included 163 patients with median time from discharge to last recorded follow-up of 30 days (interquartile range [IQR], 17-46 days). The median duration of index hospitalization was 6 days (IQR, 3-12 days) and 26% required intensive care. The cumulative incidence of thrombosis (including arterial and venous events) at day 30 following discharge was 2.5% (95% confidence interval [CI], 0.8-7.6); the cumulative incidence of venous thromboembolism alone at day 30 postdischarge was 0.6% (95% CI, 0.1-4.6). The 30-day cumulative incidence of major hemorrhage was 0.7% (95% CI, 0.1-5.1) and of clinically relevant nonmajor bleeds was 2.9% (95% CI, 1.0-9.1). We conclude that the rates of thrombosis and hemorrhage appear to be similar following hospital discharge for COVID-19, emphasizing the need for randomized data to inform recommendations for universal postdischarge thromboprophylaxis.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome coronavirus and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
    • acute respiratory syndrome coronavirus and low molecular weight heparin discharge: 1
    • acutely ill and low molecular weight: 1, 2, 3, 4, 5
    • acutely ill and low molecular weight heparin: 1, 2, 3, 4, 5
    • acutely ill and low molecular weight heparin discharge: 1
    • acutely ill medical population and low molecular weight: 1
    • acutely ill medical population and low molecular weight heparin: 1
    • acutely ill medical population and low molecular weight heparin discharge: 1